1	Role of FYVE and Coiled-Coil Domain Autophagy Adaptor 1 in severity of COVID-19
2	infection
3	
4	Sandra P. Smieszek ¹ , Mihael H. Polymeropoulos ¹
5	
6	
7	¹ Vanda Pharmaceuticals Inc., 2200 Pennsylvania NW, Suite 300-E, Washington, DC 20037
8	
9	
10	
11	Corresponding author
12	sandra.smieszek@vandapharma.com
13	
14	
15	
16	
17	
18	
19	
20	
21 22	
22 73	
23	
25	
26	
27	
28	
29	
30	
31	

32

33 Abstract

Coronaviruses remodel intracellular membranes to form specialized viral replication compartments, such as double-membrane vesicles where viral RNA genome replication takes place. Understanding the factors affecting host response is instrumental to design of therapeutics to prevent or ameliorate the course of infection.

38

As part of explorative tests in hospitalized patients with confirmed COVID-19 infection 39 40 participating in ODYSSEY trial, we obtained samples for whole genome sequencing analysis as well as for viral genome sequencing. Based on our data, we confirm one of the strongest severity 41 42 susceptibility locus thus far reported in association with severe COVID-19: 3p21.31 locus with 43 lead variant rs73064425. We further examine the associated region. Interestingly based on LD analysis we report 3 coding mutations within one gene in the region of FYVE and Coiled-Coil 44 45 Domain Autophagy Adaptor 1 (FYCO1). We specifically focus on the role of FYCO1 modifiers and gain-of-function variants. We report the associations between the region and clinical 46 47 characteristics in this severe set of COVID-19 patients.

48

We next analyzed expression profiles of *FYCO1* across all 466 compounds tested. We
selected only those results that showed a significant reduction of expression of *FYCO1*. The most
significant candidate was indomethacin – an anti-inflammatory that could potentially
downregulate *FYCO1*. We hypothesize that via its direct effects on efficiency of viral egress, it
may serve as a potent therapeutic decreasing the replication and infectivity of the virus. Clinical
studies will be needed to examine the therapeutic utility of indomethacin and other compounds
downregulating *FYCO1* in COVID-19 infection and other strains of betacoronaviruses.

57 Keywords: COVID-19, therapeutics, whole genome sequencing, viral genetics, blocking viral58 egress

59

61 Introduction

62 The emergence of highly pathogenic zoonotic viruses calls for further research in order to 63 understand, treat and ideally prevent such infections ultimately circumventing epidemics. 64 Currently accurate prognoses are confounded by our inability to predict disease severity and 65 virulence across space and time. Virus-human interactions have driven around 30% of the human 66 genome evolution since divergence from chimpanzee. Different variants, genes affect severity to 67 a range of infections, for example: IFITM3, IRF7 in influenza, SFPA/D and VTR in RSV, CCR5 in HIV, *IFNG* in HTVL-1 and *TNF* in HPV to name a few. The complex interplay between 68 69 environmental, viral, and host genetic factors drives differences in individual disease progression, severity, and outcome results. Understanding resilience and susceptibility factors 70 71 should enable one to design prophylactics and therapeutics.

72

SARS-CoV-2 is a novel coronavirus that has led to a worldwide pandemic¹. There is a 73 74 high mortality rate associated with the virus and despite measures implemented to contain the 75 spread of the virus, over xx were reported. The ACE2 binding affinity with RBD on the Spike 76 protein of SARS-CoV-2 is 10-20x higher than that of the SARS-CoV. The clinical spectrum of 77 this disease is heterogeneous, and infected individuals viral RNA shedding pattern differ across individuals at baseline. Similarly to other positive-sense RNA viruses, coronaviruses remodel 78 79 intracellular membranes to form specialized viral replication compartments. Depending on the 80 time course of the infection, the structure, composition, and formation of virus replication 81 organelles appear to be varied and dynamic. Understanding the mode of action of this virus in 82 the context of its interaction with the host genome is fundamental to the design of optimal 83 therapeutic strategies.

84 In the early months of the epidemic it became apparent that advanced age and comorbidities are associated with higher risk for severe infection yet none of these fully explain 85 the heterogeneous course of the infection amongst individuals². To that end several sequencing 86 87 projects have been commenced since the beginning of the epidemic. Initial results from COVID-88 19 initiative suggest a locus on chromosome 3p21.31, the peak association with severity of the 89 disease, signal that has been observed by the Severe Covid-19 GWAS Group and further replicated by other host genome sequencing consortia³⁴⁵ and the UKbiobank⁶. The genetic 90 variants on chromosome 3 that are most associated with severe COVID-19 are all in high linkage 91

92 disequilibrium (LD). Furthermore recent phylogenetic analysis showed that the risk haplotype 93 thus entered the modern human population from Neanderthals (Vindija 33.19 Neanderthal)⁷. 94 Specifically, we focused on this region is because the 3p21.31 regional severity association was 95 the strongest one replicated by multiple consortia including the COVID-19 initiative and latest 96 Nature report by Casteneira et al., (rs73064425, OR=2.14, discovery $p=4.77 \times 10-30$) (top 97 variants can be accessed in the supplementary material) 98 99 As part of explorative tests in hospitalized patients with confirmed SARS-CoV-2 positive 100 infection participating in ODYSSEY trial, we obtained blood samples for whole genome 101 sequencing analysis as well as nasopharyngeal swabs for further viral genome sequencing. We 102 have conducted whole genome sequencing on first cohort participants as well as deep clinical phenotyping. Based on our data, we confirm one of the strongest susceptibility locus reported 103 and now replicated with lead variant being rs73064425. We further examine the associated 104 105 region, with specific focus on the role of FYCO1 gene. We further discuss the associations 106 between the region and clinical characteristics in this severe set of COVID-19 patients. 107 108 109

110 **Results**

111 Regional association

112 We replicate the strongest susceptibility locus reported and now replicated is within, 3p21.31 113 locus, rs73064425 Leucine Zipper Transcription Factor Like 1 (LZTFL1) reported by Casteneira 114 et al., as the strongest association with severity (rs73064425, OR=2.14, discovery $p=4.77 \times 10^{-10}$ 115 30). We replicate this association in our cohort of hospitalized patients (OR 3.2, CI 116 1.8728 to 5.4637, p-value<0.0001). The variant has a global gnomAD MAF of 0.05. We report 117 an increased MAF 0.19 in ODYSSEY, and consistently with gnomAD, we report a MAF of 0.05 118 in Vanda 2000 controls. The highest allelic frequency for this variant globally is present in Ashkenazi Jewish (MAF 0.12) and the lowest frequency is present amongst East and South 119 120 Asian populations (MAF 0.0006). The GWAS signal covers a cluster of six genes (SLC6A20, LZTFL1, CCR9, FYCO1, CXCR6, and XCR1), several of which with functions that could be 121 potentially relevant to Covid-19. The variant is a strong eQTL for CXCR6 and SLC6A20 in 122 123 GTEX⁸. The locus itself is within a highly regulatory region, as an enhancer for Primary B cells 124 from peripheral blood and modifier H3K4me1 in accordance with Haploreg. Furthermore the 125 locus is associated with monocyte percentage (UK Biobank field: 30190-0.0) in Gene Atlas.

126

127 Next we reconstructed LD to test if the signal (non-coding, top SNP by p-value) from 128 other large studies can be reproduced and extended to nearby genes, Where are the "limits" of 129 the signal on Odyssey data, Are there any coding variants .Interestingly there are 3 coding 130 mutations within one gene in the region (FYCO1) causing 2 amino acid substitutions (two 131 mutations within same codon, 1001, resulting in one missense mutation, third in strong LD). All 132 3 coding variants are in strong LD with top SNPs published previously within the region and 133 seem to be the strongest signal for our Odyssey samples. Having ~2000 control genomes we can 134 see that all 3 coding variants form a strong LD. Quintessentially the risk is conveyed by the 135 extent of existing LD structure in that region as shown in Supplementary Figures. Specifically, 136 rs33910087 is an eQTL for CXCR6 and based on GeneAtlas, the genotyped variant is highly 137 significant modifier of monocyte percentage (p=3.8479e-46).

138

The association of the locus with severity of infection in interaction with SARS-CoV-2
remains to be examined. Functionally *FYCO1* encodes a protein involved in vesicle transport and

141 autophagy. It has been suggested as a key mediator linking ER-derived double membrane vesicles, the primary replication site for coronaviruses, with the microtubule network⁹. FYCO1 142 143 through its LC3-interacting region (LIR) motif was shown to be important for the fusion of 144 autophagosomes with lysosomes. FYCO1 dimerizes via the CC region, interacts with PI3P via 145 its FYVE domain, and forms a complex with Rab7 via a part of the CC region located in front of the FYVE domain⁹. Specifically, *FYCO1* was shown to act as a Rab7 effector that binds to LC3 146 and PI3P to mediate microtubule plus end-directed vesicle transport¹⁰. The depletion of Rab7 147 inhibits maturation of late endosomes/MVBs and leads to reduced lysosome numbers in cells¹¹. 148 149 *FYCO1* also mediates clearance of α synuclein aggregates through a Rab7 dependent mechanism, overexpression reducing number of cell with $\alpha \Box$ synuclein aggregates¹². In another 150 151 recent report authors perform a genome-scale CRISPR loss-of-function screen in human alveolar basal epithelial carcinoma cells to identify genes whose loss enabled resistance to SARS-CoV-2 152 viral infection¹³. Loss of RAB7A reduces viral entry/egress by sequestering the ACE2 receptor 153 inside cells¹³. Furthermore, depletion of *FYCO1* or antibodies against the N-terminus of LC3 154 155 blocks the subcellular redistribution of autophagosomes¹⁴. Indeed, rare *FYCO1* variants some of 156 which contain missense mutations in the LIR domain have recently been associated with 157 inclusion body myositis a disease characterized by impaired autophagic degradation. 158

We stipulate gain of function variants in *FYCO1* confer higher risk of severe course of COVID-19 induced infection and likely other betacoronaviruses. Temporarily downregulating *FYCO1* seems to be protective, hence the locus is likely crucial to designing therapeutic strategies for this and other strain of betacoronaviruses.

163

164 FYCO1 and drug-gene expression

165 We have conducted a high throughput drug screen gene expression analysis to identify

166 compounds that would downregulate the expression of *FYCO1*. To discover potential,

- 167 pharmaceutical agents capable of affecting transcriptional expression levels of *FYCO1*
- 168 implicated in SARS-CoV and SARS-CoV2 patho-physiology, we have screened 466 compounds
- belonging to 14 different therapeutic classes. Screening was conducted using human retinal
- pigment epithelia cell line (ARPE-19) and gene expression changes were collected across 12,490
- 171 genes. We analyzed the expression profiles of *FYCO1* across all 466 compounds tested. In order

172 to find positive hits we selected only those results that showed a reduction of expression of 173 FYCO1 (1.5 -fold difference). The top significant candidate indomethacin is (displayed in **Table** 174 1) a drug that has both anti-inflammatory and antiviral actions. Indomethacin was previously 175 shown to have potent direct antiviral activity against the coronaviruses SARS-CoV and CCoV. 176 Its potent antiviral activity (>1,000-fold reduction in virus yield) was previously confirmed in vivo in CCoV-infected dogs (Amici). These screens warrant further confirmatory tests 177 178 nevertheless the strategy to weaken viral egress could be potentially useful for strains beyond 179 SARS-CoV-2

180

Compound	FYCO1	FYCO1	FYCO1
	Log2(treated)	Log2(Ctrl)	Log2(diff)
Indomethacin	4.94	6.48	1.53
Primidone	6.44	7.94	1.49
TriprolidineHydrochloride	6.49	7.98	1.49
Baclofen	6.72	7.94	1.21

181

182 *Table 1*.

183

184 Clinical Characteristics of carriers

185 Both heterozygotes and homozygotes were severe hospitalized patients treated for COVID-19. 186 The signal is one of severity however we wanted to check if the variant carriers would have any 187 particular clinical characteristics. To that end we tested systemic cytokine panel in addition to 188 standard lab tests. Clinical characteristics across genotypes are displayed in **Supplementary** 189 Material. Noticeable is the linear distribution with higher sodium and chloride seen in 190 homozygous individuals. All study patients met inclusion criteria included: age 18-90; confirmed 191 laboratory COVID-19 infection; confirmed pneumonia by chest radiograph or computed 192 tomography; fever defined as temperature \geq 36.6 °C armpit, \geq 37.2 °C oral, or \geq 37.8 °C rectal 193 since admission or the use of antipyretics; $PaO2 / FiO2 \le 300$; 6. in-patient hospitalization. We 194 furthermore sequenced the viral genome sequence data in conjunction with host sequencing. We report coding mutations in SARS-CoV-2 based CoV-GLUE annotations¹⁵. All known variants 195 reported in CoV-Glue¹⁵ (until 11/23/2020) variants were annotated. As the viral strains evolved, 196 197 the 614th as position of the S protein, aspartate became replaced by glycine ultimately becoming

the ubiquitous strain, hence making open conformations more likely. All patients are carriers of
the S:D614G variant - variant in the spike protein D614G that rapidly became dominant strain
according to latest GISAID data^{16,17}.

201

202 Discussion

Coronaviruses remodel intracellular membranes to form specialized viral replication compartments, such as double-membrane vesicles where viral RNA genome replication takes place. Understanding the formation and operation of these vesicles is instrumental to optimal design of therapeutics to prevent or ameliorate the course of infection. Here via findings from whole genome sequencing and association with severity of COVID-19, we were led to a locus that may in fact be functionally relevant in predisposing individuals to severe course of infection via its direct effects on efficiency of viral egress.

210

211 FYCO1 has a direct link to formation of vesicles and autophagy. Pathogenic mutations in FYCO1 can affect intracellular transport of autophagocytic vesicles. Depletion of FYCO1 has 212 been shown to block distribution of autophagosomes. FYCO1 also mediates clearance of 213 214 α synuclein aggregates through a Rab7 dependent mechanism, overexpression reducing 215 number of cell with $\alpha \Box$ synuclein aggregates. Recently using single cell RNAseq authors 216 identified a group of genes (ATP6AP1, ATP6V1A, NPC1, RAB7A, CCDC22, and PIK3C3) whose knockout induced shared transcriptional changes in cholesterol biosynthesis pathway¹³. 217 218 They showed how the actual perturbation of the cholesterol biosynthesis pathway reduced viral 219 infection. That furthermore reveals the links via RAB7. We hypothesize fewer pLOFs in NPC1 220 to be present in cohorts of severe hospitalized patients with COVID-19. Niemann-Pick disease 221 type C1 lipid storage disorder offers resistance to Ebola in cell line experiments and in homozygous recessive mice ((Npc1- /-))¹⁸,¹⁹. Furthermore, bat species show selective sensitivity 222 to Ebola versus Marburg viruses²⁰. Our hypothesis is that people with certain lysosomal storage 223 224 diseases may be resistant to one of these viruses. Along these lines there is suggestive evidence 225 for this to be exactly the case. This is in line with a report by Sturley et al., authors propose that 226 50 loci that in the homozygous state cause a lysosomal storage disorder, may account for 227 divergent clinical outcomes in COVID-19.

228

229 Blocking or perturbing viral egress whether via Rab7, FYCO1 or other components may 230 be a viable strategy to stop the proliferation of the virus reducing viral load. In the case of 231 betacoronaviruses unconventional egress can be blocked by the Rab7 GTPase competitive inhibitor CID1067700¹¹ - compound potently decreasing viral egress in a dose-dependent 232 233 manner. Here we focused on downregulation of FYCO1: based on cell line expression with 234 resulting potential candidates including indomethacin - a drug that has both anti-inflammatory 235 and antiviral actions. Slowing viral spread by targeting regulators of lysosomal trafficking, by 236 focusing on egress and double membrane vesicles may offer a therapeutics strategy for novel 237 strain of betacoronaviruses.

- 238
- 239

240 The GWAS locus has led for further understanding of not only the more efficient egress

leading to successful propagation of the viral particles but also to potential protective

242 mechanisms and greater understanding of the heterogeneous clinical outcomes. We hence

stipulate gain of function variants in FYCO1 confer higher risk of infection with SARS and other

betacoronaviruses. Downregulating or temporarily limiting, *FYCO1* activity may be protective.

245 This susceptibility locus in fact highlights the potentially druggable cellular aspects of the host.

246

247 Methods

248 Clinical Trial Information

249 ODYSSEY is a double-blinded Phase 3 study with a planned randomization of a total of 300

250 hospitalized severely ill COVID-19 patients to receive either tradipitant 85 mg bid or placebo for

a total of up to 14 days or discharge (CONSORT Flowchart in S. File 1). The randomization is

stratified by site with a block size of four. Inclusion criteria for the study comprised of: 1. Adults

aged 18-90; 2. confirmed laboratory COVID-19 infection; 3. confirmed pneumonia by chest

radiograph or computed tomography; 4. fever defined as temperature \geq 36.6 °C armpit, \geq 37.2 °C

oral, or \geq 37.8 °C rectal since admission or the use of antipyretics; 5. PaO2 / FiO2 \leq 300; 6. in-

- 256 patient hospitalization. Patients were to be followed for up to 28 days to record clinical
- 257 outcomes. Patients' clinical progress was recorded on a 7 point clinical status ordinal scale
- defined as follows: 1- Death; 2- Hospitalized on mechanical ventilation or ECMO; 3-
- 259 Hospitalized on non-invasive ventilation or high-flow oxygen supplementation; 4- Hospitalized

- 260 requiring supplemental oxygen; 5- Hospitalized not requiring supplemental oxygen, requiring
- 261 continued medical care; 6- Hospitalized not requiring supplemental oxygen, not requiring
- 262 continued medical care; 7- Not hospitalized.
- 263
- 264 Human whole genome sequencing

265 Vanda Pharmaceuticals Inc. COVID-19 Cohort:

WGS cohort consisted of 80 COVID-19 hospitalized patient samples and 1876 WGS controls.
DNA was extracted from 200 µl of whole blood using QIAamp blood mini kit and eluted into

268 100 µl volume in order to obtain 500 ng of DNA. Libraries were prepared by random

- 269 fragmentation of DNA followed by adapter ligation using Illumina TruSeq adapters. Paired-end
- libraries 2x150 bp were sequenced on an Illumina NovaSeq6000 S4 with a target of 90Gb raw

271 read depth per sample. The cohort was multi-ethnic and the age ranged from 35-87 for severe

- hospitalized COVID-19 cases (68% male, 32% female). Specifically the PC defined ancestry
- was as follows (African 9.8%, European 46.3%, Asian 4.9%, Hispanic 22% and other 17.1%).
- Furthermore, 16% of the cohort were patients hospitalized on mechanical ventilation or ECMO,

275 13% deceased.

276 Both cases and controls were processed with the same bioinformatic pipeline for variant calling.

- 277 Paired-end 150 bp reads were aligned to the GRCh37 human reference (BWA-MEM v0.7.8)
- followed by Picard (MarkDuplicates) and processed with GATK best-practices workflow
- 279 (GATK v3.5.0). The mean coverage was 35.8x. All high quality variants obtained from GATK
- 280 were annotated. Annotations include variant effect predictions using VEP; allele frequencies

from Gnomad;dbSNP 150 rsIDs; conservation scores from PhyloP, GERP, PhastCons; damaging

282 effect predictions from Polyphen 2, SIFT and clinically relevant information from ClinVar. We

- removed samples with a discordance between self-declared and sequence-derived gender, we
- used KING for detection of related individuals and performed PCA for ancestry adjustment. The

285 lead variant was in addition verified with genotyping (Supplementary Material). Logistic

- regression was conducted in PLINK, MATLAB. The analysis was corrected for PC 1-15, age
- 287 and sex.

288 Viral sequencing and genome assembly

Sequencing was attempted on all samples with a positive RT-PCR assay result that had Ct <32 289 using either a metagenomic approach described previously²¹, via IDT probe-capture²², or by 290 291 amplicon sequencing with SWIFT library preparation. Libraries were sequenced on Illumina 292 MiSeq or NextSeq instruments using 1x150 or 1x75 runs respectively. Consensus sequences 293 were assembled using a custom bioinformatics pipeline [https://github.com/proychou/hCoV19] adapted for SARS-CoV-2 from previous work²²,²³. Briefly, raw reads were trimmed to remove 294 295 adapters and low quality regions using BBDuk and a k-mer based filter was used to pull out 296 reads matching the reference sequence NC 045512. Filtered reads were *de novo* assembled using SPAdes²⁴ and contigs were ordered against the reference using BWA-MEM. Gaps were filled by 297 298 remapping reads against the assembled scaffold and a consensus sequence was called from this alignment using a custom script in R/Bioconductor. 299

300

301 Cell culture and drug treatment

Drugs screening was carried out, the same one as applied in our previous study²⁵. The retinal 302 303 pigment epithelia cell line, ARPE-19/HPV-16, was chosen to establish a database of drug 304 profiles because of its non-cancerous, human origin, with a normal karyotype. It can also be 305 easily grown as monolayer in 96-well plates. Compounds were obtained from Sigma (St. Louis, 306 MO) or Vanda Pharmaceuticals (Washington, DC). Cells were aliquoted on 96-well plates 307 $(\sim 2 \times 10e5 \text{ cells/well})$ and incubated for 24 h prior to providing fresh media with a drug, or the 308 drug vehicle (water, dimethyl sulfoxide, ethanol, methanol, or phosphate-buffered saline 309 solution). Drugs were diluted 1000 fold in buffered in Dulbecco's Modified Eagle Medium: 310 Nutrient Mixture F-12 (D-MEM/F-12) culture medium (Invitrogen, Carlsbad, CA) containing 311 nonessential amino acids and 110 mg/L sodium pyruvate. In these conditions, no significant 312 changes of pH were expected, which was confirmed by the monitoring of the pH indicator 313 present in the medium. A final 10 µM drug concentration was chosen because it is believed to fit in the range of physiological conditions²⁵. Microscopic inspection of each well was conducted at 314 315 the end of the treatment to discard any samples where cells had morphological changes 316 consistent with apoptosis. We also verified that the drug had not precipitated in the culture 317 medium.

318

319 Gene expression

320 Cells were harvested 24 h after treatment and RNA was extracted using the RNeasy 96 protocol 321 (Qiagen, Valencia, CA). Gene expression for 22,238 probe sets of 12,490 genes was generated 322 with U133A2.0 microarrays following the manufacturer's instructions (Affymetrix, Santa Clara, 323 CA). Drugs were profiled in duplicate or triplicate, with multiple vehicle controls on each plate. 324 A total of 708 microarrays were analyzed including 74 for the 18 antipsychotics, 499 for the 325 other 448 compounds, and 135 for vehicle controls. The raw scan data were first converted to 326 average difference values using MAS 5.0 (Affymetrix). The average difference values of both 327 treatment and control data were set to a minimum of 50 or lower. For each treatment category, 328 all probe sets were then ranked based on their amplitude, or level of expression relative to the 329 vehicle control (or the average of controls was selected when more than one was used). 330 Amplitude was defined as the ratio of expression (t-v) / [(t+v) / 2] where t corresponds to treatment instance and v to vehicle instance. Each drug group profile was created using our novel 331 332 Weighted Influence Model, Rank of Ranks (WIMRR) method which underscores the rank of 333 each probe set across the entire gene expression profile rather than the specific change in 334 expression level. WIMRR takes the average rank of each probe set across all of the members of 335 the group and then reranks the probe sets from smallest average rank to largest average rank. A 336 gene-set enrichment metric based on the Kolmogorov- Smirnov (KS) statistic. Specifically, for a 337 given set of probes, the KS score gives a measure of how up (positive) or down (negative) the set 338 of probes occurs within the profile of another treatment instance. 339 340 Declarations

341 **Funding**: Vanda Pharmaceuticals Inc.

342 **Competing Interests**: SPS, BPP, MHP are employees of Vanda Pharmaceuticals.

343 Ethical Approval: Reviewed and approved by Advarra IRB; Pro00043096

- 345
- 346

347 **References**

- Zhu, N. *et al.* A Novel Coronavirus from Patients with Pneumonia in China, 2019. *New England Journal of Medicine* 382, 727–733 (2020).
- 2. Zhou, F. *et al.* Clinical course and risk factors for mortality of adult inpatients with
- 351 COVID-19 in Wuhan, China: a retrospective cohort study. *The Lancet* 395, 1054–1062
 352 (2020).
- Ganna, A., Unit, T. G. & General, M. The COVID-19 Host Genetics Initiative, a global
 initiative to elucidate the role of host genetic factors in susceptibility and severity of the
 SARS-CoV-2 virus pandemic. 715–718 (2020). doi:10.1038/s41431-020-0636-6
- Genomewide Association Study of Severe Covid-19 with Respiratory Failure. *New England Journal of Medicine* 383, 1522–1534 (2020).
- 358 5. Pairo-Castineira, E. *et al.* Genetic mechanisms of critical illness in Covid-19. *medRxiv* 17,
 359 25 (2020).
- Karczewski, K. J. *et al.* Variation across 141,456 human exomes and genomes reveals the
 spectrum of loss-of-function intolerance across human protein-coding genes. *bioRxiv*531210 (2019). doi:10.1101/531210
- 363 7. Zeberg, H. & Pääbo, S. The major genetic risk factor for severe COVID-19 is inherited
 364 from Neanderthals. *Nature* (2020). doi:10.1038/s41586-020-2818-3
- 365 8. Lonsdale, J. *et al.* The Genotype-Tissue Expression (GTEx) project. *Nature Genetics* 45, 580–585 (2013).
- 367 9. Zhang, J., Lan, Y. & Sanyal, S. Membrane heist□: Coronavirus host membrane
 368 remodeling during replication. (2020).
- Pankiv, S. *et al. FYCO1* is a Rab7 effector that binds to LC3 and PI3P to mediate
 microtubule plus end Directed vesicle transport. *Journal of Cell Biology* 188, 253–269
 (2010).
- 11. Ghoush Amit Kumar Mandal, Paulami Dam, Octavio L. Franco, Hanen Sellami,
- 373 Sukhendu Mandal, Gulten Can Sezgin, Kinkar Biswas, Partha Sarathi Nandi, I. O. b-
- 374 Coronaviruses Use Lysosomes for Egress Instead of the Biosynthetic Secretory Pathway.
 375 *Cell* 19–21 (2020).
- 376 12. Saridaki, T. *et al. FYCO1* mediates clearance of α-synuclein aggregates through a Rab7377 dependent mechanism. *Journal of Neurochemistry* 146, 474–492 (2018).

378	13.	Daniloski, Z. et al. Identification of required host factors for SARS-CoV-2 infection in
379		human cells. Cell 1-14 (2020). doi:10.1016/j.cell.2020.10.030
380	14.	Reggiori, F., de Haan, C. A. M. & Molinari, M. Unconventional use of LC3 by
381		coronaviruses through the alleged subversion of the ERAD tuning pathway. Viruses 3,
382		1610–1623 (2011).
383	15.	Singer, J., Gifford, R., Cotten, M. & Robertson, D. CoV-GLUE: A Web Application for
384		Tracking SARS-CoV-2 Genomic Variation. Preprints 2020060225 (2020).
385		doi:10.20944/PREPRINTS202006.0225.V1
386	16.	Elbe, S. & Buckland-Merrett, G. Data, disease and diplomacy: GISAID's innovative
387		contribution to global health. Global Challenges 1, 33-46 (2017).
388	17.	Grubaugh, N. D., Hanage, W. P. & Rasmussen, A. L. Making Sense of Mutation: What
389		D614G Means for the COVID-19 Pandemic Remains Unclear. Cell 182, 794–795 (2020).
390	18.	Withrock, I. C. et al. Genetic diseases conferring resistance to infectious diseases. Genes
391		& Diseases 2, 247–254 (2015).
392	19.	Takadate, Y. et al. Niemann-Pick C1 Heterogeneity of Bat Cells Controls Filovirus
393		Tropism. Cell Reports 30, 308–319.e5 (2020).
394	20.	Haines, K. M., Vande Burgt, N. H., Francica, J. R., Kaletsky, R. L. & Bates, P. Chinese
395		hamster ovary cell lines selected for resistance to ebolavirus glycoprotein mediated
396		infection are defective for NPC1 expression. Virology 432, 20–28 (2012).
397	21.	Greninger, A. L. et al. Rapid metagenomic next-generation sequencing during an
398		investigation of hospital-acquired human parainfluenza virus 3 infections. Journal of
399		<i>Clinical Microbiology</i> 55 , 177–182 (2017).
400	22.	Greninger, A. L. et al. Ultrasensitive Capture of Human Herpes Simplex Virus Genomes
401		Directly from Clinical Samples Reveals Extraordinarily Limited Evolution in Cell
402		Culture. <i>mSphere</i> 3 , 1–12 (2018).
403	23.	Greninger, A. L. et al. Proteomic Reannotation of Human Herpesvirus 6. 1-17 (2018).
404	24.	Bankevich, A. et al. SPAdes: A new genome assembly algorithm and its applications to
405		single-cell sequencing. Journal of Computational Biology 19, 455-477 (2012).
406	25.	Polymeropoulos, M. H. et al. Common effect of antipsychotics on the biosynthesis and
407		regulation of fatty acids and cholesterol supports a key role of lipid homeostasis in
408		schizophrenia. Schizophrenia Research 108, 134–142 (2009).

409 Figure Legend

- 410 Figure 1. Figure 1A depicts the coding variants detected in the region association with severity
- 411 of COVID-19 infection in FYCO1 gene. Figure 1B is a locus zoom of the entire significant
- 412 chromosome 3 region associated with severe COVID-19 based on a whole genome sequencing
- 413 analysis.
- 414

Chromosome 3 COVID-19

Plotted SNPs

